NANBIOSIS supports IdiPAZ project to develop protein-based therapy from extracellular vesicles to improve recovery after brain hemorrhage.
Barcelona, September, 2025 — The Protein Production Platform (PPP, NANBIOSIS Unit 1) has joined an innovative translational research project led by the Neurology and Cerebrovascular Diseases Group at the Health Research Institute of Hospital Universitario La Paz (IdiPAZ).
The project, funded by the Instituto de Salud Carlos III (ISCIII) under grant PI23/00436, focuses on the development of a new protein-based treatment to improve recovery after brain hemorrhage. The strategy involves the administration of encapsulated therapeutic proteins, representing a novel approach to enhance functional outcomes in patients. The study is coordinated by Dr. María Alonso de Leciñana and Dr. María Gutiérrez.
Proteins derived from extracellular vesicles
The therapeutic concept stems from a promising clinical observation. Proteins of interest were identified by analyzing extracellular vesicles in the peripheral blood of patients with spontaneous favorable recovery after brain hemorrhage. Previous research by the IdiPAZ group demonstrated that these vesicles carry higher levels of proteins involved in cellular repair and regeneration, particularly in patients with better neurological outcomes.
Role of NANBIOSIS Unit 1 in protein production
Currently, the selected proteins are being synthesized and purified in soluble and active form by NANBIOSIS Unit 1, which specializes in protein production and purification services for biomedical research. These proteins will then be encapsulated using advanced formulations developed by Diversa Technologies, a Spanish biotech spin-off created from the Health Research Institute of Santiago de Compostela (IDIS).
Collaborative research for biomedical innovation
The identification of therapeutic proteins was made possible through the collaboration of Dr. Susana Bravo, from the Proteomics Unit of IDIS. Following preclinical validation in experimental models, this strategy could open the way to a novel therapy to enhance neurological recovery in brain hemorrhage patients.
This initiative highlights the role of NANBIOSIS research infrastructure in advancing translational medicine, nanomedicine, and biotechnology. By providing state-of-the-art protein production capabilities, NANBIOSIS fosters collaborations that transform promising laboratory discoveries into potential clinical applications.
What is NANBIOSIS?
The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).
In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.
NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:
